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Brain-derived neurotrophic factor (BDNF), a member of the nerve growth factor family of neurotrophins, has central roles in the development,
physiology, and pathology of the nervous system. We have elucidated the structure of the human BDNF gene, identified alternative transcripts, and
studied their expression in adult human tissues and brain regions. In addition, the transcription initiation sites for human BDNF transcripts were
determined and the activities of BDNF promoters were analyzed in transient overexpression assays. Our results show that the human BDNF gene
has 11 exons and nine functional promoters that are used tissue and brain-region specifically. Furthermore, noncoding natural antisense RNAs that
display complex splicing and expression patterns are transcribed in the BDNF gene locus from the antiBDNF gene (approved gene symbol
BDNFOS). We show that BDNF and antiBDNF transcripts form dsRNA duplexes in the brain in vivo, suggesting an important role for an-
tiBDNF in regulating BDNF expression in human.
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the nerve growth factor family of neurotrophins. During deve-
lopment BDNF supports the survival and differentiation of
selected neuronal populations of the peripheral and central
nervous systems and participates in axonal growth and
pathfinding and in the modulation of dendritic growth and
morphology [1,2]. BDNF also has a prominent role in later
stages of nervous system development and in the adult by
regulating synaptic transmission and plasticity and acts as a
central modulator of pain [3]. BDNF has been shown to be a
modulator of synaptogenesis in vivo [4] and has a functional
role in the expression of LTP in the hippocampus [5]. Data
accumulated in recent years suggest that neuronal activity
regulates transcription of BDNF, transport of BDNFmRNA and☆ Sequence data from this article have been deposited in the GenBank
Data Libraries under Accession Nos. EF674517 - EF674521 and EF689009 -
EF689021 (human BDNF mRNAs), and EF689022 - EF689042 (human
antiBDNF RNAs).
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Open access under CC BY license.protein into dendrites, and secretion of BDNF protein, which
are important for the formation of appropriate synaptic con-
nections and for learning and memory during development and
in adults [6]. A single-nucleotide polymorphism in the human
BDNF gene, resulting in a valine to methionine substitution
(Val66Met) in the prodomain, has been shown to lead to
reduced activity-induced BDNF secretion and memory impair-
ment [7]. BDNF signaling has been shown to be critical in
several neuropsychiatric and neurodegenerative diseases [1], for
example, Huntington disease [8]. These results taken together
show that BDNF has numerous important roles in brain
development, physiology, and pathology.
During development, BDNF protein expression is more
abundant in the nervous system compared to other tissues and
its levels are dramatically increased in the brain during postnatal
development [9]. In the adult nervous system, BDNF displays a
widespread distribution pattern, with the highest levels of
mRNA and protein in the hippocampus, amygdala, cerebral
cortex, and hypothalamus [9–12]. BDNF mRNA expression is
mostly confined to neurons and there are only a few brain areas
where BDNFmRNA is not detected [10–12]. BDNF expression
in adult tissues is detectable also outside of the central nervous
398 P. Pruunsild et al. / Genomics 90 (2007) 397–406system. Lower BDNF mRNA levels than in the hippocampus
have been detected in the thymus, liver, spleen, heart, and lung
[9,11,13,14].
The structure and regulation of the BDNF gene have been
studied in rodents [15–17]. Mouse and rat BDNF genes have
eight 5′ exons containing separate promoters upstream of each
exon and one 3′ exon encoding the mature BDNF protein [17].
Multiple promoters determine tissue-specific expression of the
BDNF transcripts [15,17]. The human BDNF has also been
shown to consist of multiple 5′ noncoding exons and one
coding exon, which give rise to alternatively spliced transcripts
[18–20]. According to the most recent description of the
organization of the human BDNF gene locus and alternatively
spliced transcripts the human BDNF has seven noncoding and
one coding exon [19]. Provided that only a partial description of
the transcripts was given and expression of the alternative tran-
scripts was studied in only a few brain regions and was not
investigated in human nonneural tissues, we undertook the
current study to analyze thoroughly the structure of the human
BDNF gene, characterize the expression of alternatively spliced
BDNF mRNAs in different human tissues and brain regions,
and identify and study the activities of alternative human BDNF
promoters.
Results
Structure and alternative splicing of human BDNF and
antiBDNF (approved gene symbol BDNFOS)
To reexamine the human BDNF gene structure and identify
mRNAs transcribed from the gene, in silico analysis, 5′ rapid
amplification of cDNA ends (5′ RACE), and RT-PCR analyses
were performed. First, all BDNF mRNAs and expressed se-
quence tags (ESTs) available at the NCBI database (http://www.
ncbi.nlm.nih.gov) were analyzed. Primers designed for PCR
analyses are presented in Supplementary Table 1. Total RNAs
of the adult human frontal cerebral cortex, medulla, and
hippocampus were used as templates in the RT-PCR. Second, to
identify novel BDNF transcripts and to determine the trans-
cription start sites for the human BDNF transcripts, 5′ RACE of
human adult hippocampal and cerebellar RNA was performed
using antisense primers specific for the 3′ exon and for the 5′
exons (Supplementary Table 1).
BDNF gene exon–intron boundaries and genomic locations
were determined by BLAT algorithm (http://genome.ucsc.edu/
cgi-bin/hgBlat) and by direct comparison of PCR-amplified
sequences with genomic DNA sequence from the NCBI
database (Accession No. AF411339). The designation of the
human BDNF exons in this study is consistent with the naming
of the mouse and rat BDNF exons described in the study by
Aid et al. [17]. The exons unique to human BDNF are marked
with the letter “h” and are named with the same number as the
neighboring upstream exon. Our analysis showed that the
human BDNF gene spans ∼70 kb and consists of 11 exons
(Fig. 1). hBDNF exons named by Liu et al. [19] are designated
here as old exons. Comparison of our data with that of Liu et
al. [19] shows that exons I–IV correspond to the respective oldexons; exons V, Vh, VIII, and VIIIh are novel exons; exons VI
and VII correspond to old exons V and VI, respectively; and
exon IX variants IXb and IXd correspond to old exons VII and
VIII, respectively (Fig. 2A). Nine of the exons, I, II, III, IV, V,
Vh, VI, VII, and IX, can be defined as 5′ exons (Fig. 1).
Cloning and sequencing of the 5′ RACE products revealed that
the transcription start sites relative to the 3′ end of the
respective exon are located as follows: −647 and −428 nt for
exon I; −433, −423, −422, −416, −407, −400, −226, −224,
−204, −200, −78, and −47 nt for exon II; −237 and −191 nt
for exon III; −337, −333, −274, and −215 nt for exon IV;
−82, −80, and −79 nt for exon V; −225 and −222 nt for exon
Vh; −324; −323, −319, −318, and −315 nt for exon VI; and
−184 nt for exon VII (Supplementary Fig. 1). We determined
that human BDNF transcription starts also from the last exon,
exon IX, −1102 nt upstream of the translation start site in this
exon (Supplementary Fig. 1). No major differences in the
transcription start site locations were observed when 5′ RACE
products from hippocampal or cerebellar RNA were analyzed.
Two exons, VIII and VIIIh, are rarely used and always in
combination with exon V as the 5′ exon (Fig. 1). Exons II, III,
IV, V, Vh, VI, and VIIIh are untranslated exons and translation
of the transcripts containing these exons starts from the ATG
positioned in exon IX (Supplementary Fig. 1). Exons I, VII,
and VIII contain in-frame ATG codons that could be used as
translation start sites leading to the prepro-BDNF proteins with
longer N-termini (Fig. 2B).
In addition, we identified alternative splice donor sites in
exons II, V, and VI (Fig. 1, Supplementary Fig. 1, and Table 2).
Usage of these splice sites leads to the formation of transcripts
with different 5′ UTR lengths but does not affect the coding
region of BDNF. Characterization of the exon–intron boundary
sequences showed that not all exon–intron splice junctions
adhere to the GU–AG rule characteristic of eukaryotes. We
found that exon VII is unique because the splice donor site used
contains nucleotides GG instead of the conventional GU se-
quence (Supplementary Table 2). Exon IX, which encodes the
BDNF protein and 3′ UTR, is subjected to internal splicing and/
or transcription initiation upstream of exon IX that leads to the
generation of alternative transcripts containing variants of exon
IX. These exon IX variants comprise different regions or com-
binations of regions of exon IX that were designated “a”, “b”,
“c”, and “d” (Fig. 1). Exon IX is used mostly in conjunction
with the upstream exons (I–VIII, VIIIh), and in that case only
the most 3′ region of exon IX, IXd, is included in the mature
transcripts. On rare occasions when exon VI is the 5′ exon,
alternative splicing occurs within exon IX leading to the
inclusion of two regions, IXb and IXd, in the mRNAs. When
transcription is initiated upstream of exon IX the transcripts are
not subjected to internal splicing and contain all the regions of
exon IX: IXa, IXb, IXc, and IXd. In extremely rare cases exon
IX region “c” is spliced out (Fig. 1 and Supplementary Fig. 1).
Recently it was reported that natural antisense transcripts are
transcribed from the human BDNF gene locus [19]. We ana-
lyzed the exon–intron junctions of amplified BDNF cDNAs
and also noticed that several mRNAs are transcribed in an an-
tisense direction compared to BDNF mRNAs. This finding was
Fig. 1. Structure and alternative transcripts of the human BDNF (top) and antiBDNF (bottom) genes. The structural organization of the exons and introns was
determined by analyzing genomic and mRNA sequence data using bioinformatics, RT-PCR, and 5′ RACE. Exons are shown as boxes and introns as lines. Filled boxes
and open boxes indicate the translated regions of the exons and the untranslated regions of the exons, respectively. The numbers below the exons and above the introns
indicate their sizes. Exon and intron sizes are in base pairs, if not indicated otherwise. Arrows indicate the transcription start sites. ATG and TAG mark the positions of
the translational start and stop codons, respectively. Vertical dashed lines indicate alternative splicing sites for the respective exons. BDNF exon IX is divided into
regions “a”, “b”, “c”, and “d” as indicated in the box marking the position of exon IX. BDNF transcript names relate to the upstream exons used in front of the major 3′
exon IXd. “A”–“L”mark antiBDNF transcripts. Solid lines connecting the exons of transcripts represent the major splicing patterns of exons. Dashed lines connecting
the exons of transcripts represent the minor splicing patterns of antiBDNF. Exon numbers are shown in Roman numerals for the BDNF gene and in Arabic numerals
for the antiBDNF gene.
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Fig. 2. (A) Comparison of the human and rodent BDNF gene structures proposed by different studies. Structures presented are according to Timmusk et al. [15], Liu
et al. [16], Aid et al. [17], Aoyama et al. [20], Marini et al. [40], and Liu et al. [19] and the human BDNF gene structure determined in this study. Exons are shown as
boxes and introns as lines. The identical human exons and the rodent exons homologous to the human exons are shown in the same color in all the structures. Novel
exons determined by this study are in green (V), red (Vh), purple (VIII), and light blue (VIIIh). (B) Amino acid sequences of different potential prepro-BDNF N-
termini. Amino acids encoded by exon IX are in black and sequences encoded by alternative 5′ exons are in blue. The transcripts encoding the respective N-termini of
BDNF are listed adjacent to the N-terminal sequences.
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protection assay (data not shown). We named the gene and
transcripts transcribed from the opposite strand of BDNF as
antiBDNF (for antisense BDNF; part of it is described by Liu
and colleagues and designated as OSBDNF—Liu et al. [19]).
The antiBDNF gene spans ∼191 kb and consists of at least 10
exons (exons 1–10) and is transcribed from one promoter as
shown by our 5′ RACE analyses (Fig. 1). All intron–exon
boundaries of the antiBDNF gene are consistent with the GU–
AG consensus (Supplementary Table 2).
Exons 1–4 of the antiBDNF gene are located downstream of
the BDNF gene (Fig. 1). Exon 5, 345 bp in length, overlaps
regions IXc and IXd and exon 6 overlaps region IXa of the
BDNF coding exon. Exons 7–10 of antiBDNF are located in
the introns of BDNF. In silico and RT-PCR analyses showed
that alternative splicing from the antiBDNF pre-mRNA
produces more than 300 transcripts, but exon 1 of antiBDNF
is always used as the most 5′ exon for all the transcripts. Of
note, our bioinformatics analysis showed that antiBDNF exon 1
is in head-to-head orientation with exon 1 of Lin-7c/Mals-3/
veli3, suggesting that a bidirectional promoter controls the ex-
pression of these genes. The majority of the antiBDNF alter-
native transcripts contain exons 5 and 6, which are comple-
mentary to the BDNF protein-coding exon IX. However, in
several antiBDNF transcripts exon 5 is skipped out. In addition,
exon 5 of antiBDNF could be spliced using three alternative
splice donor sites (Fig. 1, Supplementary Fig. 2), and thelengths of exons 8 and 9 can vary because of usage of internal
alternative splice acceptor sites (Fig. 1). There are no potential
open reading frames in any of the identified mRNAs transcribed
from the antiBDNF gene, suggesting that these transcripts are
non-protein-coding, as proposed also by Liu et al. [19].
Expression of alternatively spliced BDNF and antiBDNF
mRNAs in adult human tissues
Expression of BDNF and antiBDNF transcripts was deter-
mined by RT-PCR in 22 different adult human tissues (Fig. 3).
The results showed that human BDNF alternative transcripts are
expressed in a tissue-specific manner. The levels of the majority
of the human BDNF transcripts were highest in the brain.
However, several alternative BDNF mRNAs showed relatively
high expression levels in nonneural tissues. For example, ex-
pression levels of transcripts containing exons VI and IXabcd
were high in the heart, placenta, and prostate. Transcripts con-
taining exons I, Vh, VI, and IXabcd were highly expressed in
the testis. High levels of transcripts containing exon VI were
expressed also in the lung. Several BDNF mRNAs were
expressed at moderate or low levels in the adrenal gland (exon
Vh and exon IXabcd transcripts), bone marrow (exons I, VI, and
IXabcd transcripts), kidney, muscle, stomach, spinal cord
(exons Vh and VI transcripts), liver (exon IXabcd transcripts),
small intestine (exon VI transcripts), and trachea (exons Vh, VI,
and IXabcd transcripts). Low levels of exon IXabd transcripts
Fig. 3. Semiquantitative analysis of human BDNF, antiBDNF, and control GAPDHmRNA expression in adult human tissues by RT-PCR. Roman numerals on the left
indicate the detected BDNF transcripts and the 5′ exon-specific primers used in combination with an antisense primer located in the BDNF coding region in exon IXd
(Supplementary Table 1). A, C, G, and I refer to the respective antiBDNF transcripts shown in Fig. 1.
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mRNAs containing exons II and VII were expressed ex-
clusively in the brain. Altogether, the results indicate that
transcripts containing exons II, III, IV, V, and VII are pre-
dominantly brain-specific. Transcripts containing exons I and
Vh are, in addition to brain, expressed in certain peripheral
tissues, and transcripts containing exons VI and IXabcd show
a wide pattern of expression.
antiBDNF transcripts were present at different levels in
almost all human tissues analyzed (Fig. 3). High expression of
human antiBDNF transcripts was detected in the brain, kidney,
spinal cord, and testis. Moderate levels of antiBDNF RNAwere
seen in the lung, prostate, salivary gland, spleen, stomach, and
uterus. Low antiBDNF expression levels were detected in the
adrenal gland, liver, placenta, small intestine, and trachea.
Certain alternative transcripts of antiBDNF were expressed in a
tissue-specific manner. For example, antiBDNF transcripts with
exon 10 were present in the colon and muscle, whereas trans-
cripts with exon 9 were not expressed in these tissues. Taken
together, BDNF and antiBDNF expression patterns were
distinct, although partially overlapping.
Expression of alternatively spliced BDNF and antiBDNF
mRNAs in adult human brain regions
Expression analysis of human BDNF and antiBDNF trans-
cripts in 30 different adult brain regions was performed by RT-PCR (Fig. 4). Several differences in the expression of alter-
natively spliced human BDNF transcripts were detected. The
results showed that all BDNF transcripts were expressed at high
levels in the corpus mammillare (mammillary body), pons, hip-
pocampus, frontal cortex, colliculi, and olfactory tract. All
BDNF transcripts except the ones containing exons V and VII
were expressed at high levels in the cerebellum and medulla,
and all transcripts but those containing exon IXabcd were ex-
pressed at high levels in the infundibulum. BDNF expression in
the dentate nucleus, white matter of the cerebellum, substantia
nigra, nucleus ruber (red nucleus), and epiphysis was very low.
BDNF expression was also very low in the globus pallidus,
striatum (caudate nucleus and putamen), and thalamus, with the
exception of exon IXabcd transcripts, which were expressed at
relatively high levels in these regions. In the amygdala only
transcripts containing exons I, IV, and VI were expressed at high
levels. In the corpus callosum only exon VI and IXabcd trans-
cripts were detected. Notably, comparison of expression levels
of individual transcripts in different brain areas indicated that
BDNF exon II transcript levels were much higher in the cere-
bellum than in other brain areas. Exon IXabcd mRNAs were
expressed at relatively similar levels in all brain regions, with
only infundibulum having very low expression levels. Interest-
ingly, in the brain structures that contain only glial cells and
axons and do not contain neuronal cell bodies, such as corpus
callosum and optic nerve, exon IXabcd transcripts were pre-
dominantly detected. Transcripts containing exons I, Vh, and VI
Fig. 4. Semiquantitative analysis of human BDNF, antiBDNF, and control GAPDHmRNA expression by RT-PCR in different human brain regions. Roman numerals
on the left indicate the detected BDNF transcripts and the 5′-exon-specific primers used in combination with an antisense primer located in the BDNF coding region in
exon IXd (Supplementary Table 1). A, C, and G refer to the respective antiBDNF transcripts shown in Fig. 1.
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antiBDNF transcripts were expressed in all studied brain struc-
tures at similar levels (Fig. 4).
Promoter activities of the 5′ flanking regions of human BDNF
and antiBDNF upstream exons
Since the promoter regions of the human BDNF gene have
not been analyzed previously and hypothesizing that a func-
tional promoter precedes each of the identified 5′ exon of
BDNF and that there is a promoter upstream of antiBDNF exon
1, the activities of nine potential promoter regions within the
BDNF gene (namely the upstream sequences of exons I, II,
III, IV, V, Vh, VI, VII, and IXabcd) and the region upstream of
exon 1 of antiBDNF were analyzed for transcription-promoting
activity using chloramphenicol acetyltransferase (CAT) assays.
The putative promoter regions, each ∼0.2–1.3 kb in length and
containing a part of the respective 5′ UTR and 5′ flanking
genomic sequence (Supplementary Fig. 1), were isolated and
cloned into the pBLCAT2 vector in front of the CAT gene. The
promoter constructs were transfected into human embryonic
kidney HEK293T and mouse neuroblastoma N2a cells and the
promoter activities were analyzed.The results showed that all the regions upstream of the 5′
exons of the BDNF gene and exon 1 of the antiBDNF gene
were functional and could activate CAT expression (Fig. 5).
Thus it was concluded that the regions upstream of the 5′ exons
of the BDNF gene and exon 1 of the antiBDNF gene act as
separate promoters. However, the activities of the promoters
varied and differences were detected also between the cell lines
used. The activities of promoters upstream of exons II, V, Vh,
and VII were somewhat lower compared to other promoters in
N2a cells. In HEK293T cells the activities of these promoters
could be detected only after longer reaction times. Other pro-
moters showed similar activities in both of the cell lines with
BDNF promoters upstream of exons III and VI and the an-
tiBDNF promoter being the strongest in both cell lines.
However, promoters upstream BDNF exons I, IV, and IXabcd
were slightly (about twofold) more active in HEK293T cells
than in N2a cells.
Human BDNF and antiBDNF transcripts form RNA duplexes
in adult human brain in vivo
According to our data human BDNF and antiBDNF are co-
expressed in many tissues studied. The complementary region
Fig. 5. Analyses of BDNF and antiBDNF promoter activities in HEK293T and
N2a cells. The relative activities of the 5′ flanking regions of BDNF exons I, II,
III, IV, V, Vh, VI, VII, and IXabcd and antiBDNF to promote CAT expression
are shown. The promoter regions cloned in front of the CAT gene are shown in
Supplementary Fig. 1. Note that the activities of BDNF promoters II, V, Vh, and
VII in HEK239T cells were detectable using longer reaction times. m, mock-
transfected cells, negative control.
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spans 222 nt or more depending on the splicing donor site used
for antiBDNF exon 5 (Supplementary Fig. 2 and Supplementary
Table 2). Based on this knowledge we hypothesized that if
antiBDNF has a regulatory role in BDNF expression, the com-
plementary RNAs might form RNA–RNA duplexes in vivo. To
study this hypothesis we performed a PCR-based assay. Briefly,
RNase A/T1-treated RNA from adult human cerebellum was
used as a potential double-stranded RNA (dsRNA) template for
cDNA synthesis and the existence of the duplexes was analyzedFig. 6. BDNF and antiBDNF transcripts form dsRNA duplexes in the human brain in
Briefly, total human cerebellar RNAwas DNase treated. This RNAwas divided into
used as a −RNase control (box on the right). Both RNAs were reverse transcribed
Subsequently these cDNAs were used as templates in PCR to detect BDNF/antiBD
reaction was conducted with primers Dup_S2 and haBDNF_S1. The −RT reaction w
Dup_AS. Lines indicate RNAs, double line marks the complementary region of BD
parallel with the lines and primer names are in italic. Human hippocampal cDNA syn
for all the reactions.by PCR with primers specific for the complementary region of
BDNF and antiBDNF (Supplementary Table 1). Our results
showed that BDNF/antiBDNF dsRNA duplexes are present in
the human brain in vivo (Fig. 6). Control experiments using a
primer targeting the region of antiBDNF RNA outside of the
complementary sequence in combination with a primer specific
for the complementary region and experiments using RNA
template in which the reverse transcription reaction was omitted
showed that the RNA duplex-specific product was not the result
of single-strand RNA (ssRNA) or genomic DNA contamina-
tion, respectively.
Discussion
Previous studies have revealed that the human BDNF gene
consists of seven putative 5′ exons and one protein-coding exon
[19,20]. However, the expression patterns of different exons
have not been thoroughly studied and possible linkage of these
exons to separate promoters has not been investigated. Here we
show that the human BDNF gene, extending over 70 kb, con-
tains 11 exons. The 3′ exon encodes all or most of the protein
depending on the 5′ exon used. Independent of the 5′ exon
usage, two separate polyadenylation signals in exon IX can be
utilized in BDNF transcripts. In addition, our data showed that
the human BDNF gene comprises nine functional promoters.
The structures of the human BDNF gene and transcripts
determined in this study are in good agreement with the results
obtained for the rat and mouse BDNF genes [17]. Some dif-
ferences are present, though. First, human BDNF contains two
more exons than rodent BDNF. Compared to the rat and mouse
genes [17] there is an additional exon, exon Vh, linked to a
promoter between exons V and VI. Human BDNF exon VIIIh,
which is not linked to a separate promoter, is also not present invivo. A schematic representation of the RNA duplex detection assay is shown.
two—one half was treated with RNase A/T1 (box on the left) and the other was
(RT) with a BDNF/antiBDNF complementary region-specific primer, Dup_S1.
NF duplex with primers Dup_S1 and Dup_AS. ssRNA contamination control
as used for detection of genomic DNA contamination using primers Dup_S1 and
NF exon IXd and antiBDNF exon 5. Primer positions are indicated with arrows
thesized using an oligo(dT) primer (PCR+control) was used as positive control
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sites are used in human exon IX leading to transcripts con-
taining exons IXbd and IXabd. These transcripts have not been
detected in rodents [17]. All this adds more complexity to the
regulation of human BDNF. Second, in most cases, the usage of
alternative promoters in the human BDNF gene leads to the
expression of transcripts with different 5′ UTRs and with the
protein-coding region in the common 3′ exon IXd. However,
usage of an alternative upstream in-frame translation start site
containing exon I, VII, or VIII could potentially lead to human
BDNF prepro-proteins with longer N-termini. Only the trans-
lation initiation codon within exon I is characteristic of rodent
BDNF genes, suggesting that there are more BDNF protein
isoforms in human than in rodents. Third, although the trans-
cription initiation sites are generally in good agreement with the
respective regions in rodents, we identified more transcription
start sites for human exons II and IV than had been reported
previously for the rodent BDNF respective exons. Fourth, in
contrast to the rodent BDNF genes we found that exon VIII of
the human BDNF is not used as a 5′ exon as determined by the
5′ RACE analysis. We show that in human the rarely used exon
VIII of BDNF is exclusively spliced to exon V. Exon V can also
be spliced to exon IXd without including exon VIII. Exon VIII
was not detected in any transcript other than the ones starting
with exon V, pointing to a possible functional regulation bet-
ween the usage of a certain promoter and subsequent splicing.
Similar promoter-governed splicing regulation has been iden-
tified for the human nitric oxide synthase (NOS1) [21] and
mouse bcl-X [22] genes, for example. This kind of splicing
regulation is especially interesting provided the notion that exon
VIII of BDNF contains one of the alternative ATGs that may
lead to the synthesis of a prepro-BDNF protein with an alter-
native N-terminus.
We analyzed the splicing of the human BDNF pre-mRNAs
and expression of consequent alternative mRNAs in detail. We
found that BDNF transcripts containing exons II, III, IV, V, and
VII are mostly brain-specific, whereas other BDNF mRNAs are
also expressed at variable levels in nonneural tissues. Similar to
the expression pattern of BDNF mRNAs in rodents [16,17], the
most abundant transcripts in human nonneural tissues were
transcripts containing exons VI and IXabcd that were expressed
at high levels in several tissues, particularly heart, lung, skeletal
muscle, testis, prostate, and placenta. To the best of our know-
ledge, these are the first data about the expression of alter-
natively spliced BDNF mRNAs in human nonneural tissues. In
the human brain, expression of BDNF has been studied at the
protein level using many different antibodies, the specificity of
which is not always clear [23]. Fewer data are available about
BDNF mRNA expression. In most studies on human BDNF,
mRNA expression has been studied in only some regions of
brain using postmortem tissue [23–25]. In two studies the ex-
pression of human BDNF mRNAs with alternative 5′ exons
was examined in a few adult brain regions using RT-PCR
[19,26]. Our study is the first to examine BDNF exon-specific
mRNA levels across the whole human brain, thus adding
important new data to BDNF expression in adult human brain.
In the adult human brain, high levels of BDNF mRNAs werepresent in the hippocampus, cerebral cortex, amygdala, and
cerebellum, which is similar to the previously reported data on
the BDNF expression in rodent brain [10,11,15,27,28]. BDNF
is expressed predominantly in neurons, although some studies
have identified BDNF expression also in rodent astrocytes
[29,30], microglia [31], and oligodendrocytes [32], both in vivo
and in vitro. Here we show that some of the alternatively spliced
human BDNF mRNAs, particularly transcripts containing
exons VI and IXabcd, are present in vivo in the corpus callo-
sum and optic nerve containing mostly oligodendroglial cells
and axonal projections.
Gene expression in eukaryotes is a highly coordinated pro-
cess involving regulation at many different levels, among which
the regulation of transcription is one of the most important.
Several types of cis-acting DNA sequence elements, including
promoters, contribute to this process. About 18% of human
genes have multiple promoters, which regulate and increase
their transcriptional and translational potential [33]. Human
BDNF promoter IV is the only promoter of the human BDNF
gene that had been characterized so far [18]. In this study we
show that BDNF gene expression is under the control of at least
nine alternative tissue-specific promoters linked to separate 5′
exons. Alternative promoters of the BDNF gene could also be
involved in developmental stage-specific expression and cell-
type-specific expression, giving additional flexibility to the
control of BDNF expression. Therefore, the data presented in
this study show that the expression of the human BDNF gene is
highly regulated at the level of transcription.
One of the results of our study was the characterization of
endogenous noncoding antisense RNAs transcribed from the
human BDNF gene locus. According to our data the antiBDNF
gene consists of 10 exons and one functional promoter upstream
of exon 1. We show that antiBDNF transcripts are expressed in
almost all adult human tissues analyzed. High levels of an-
tiBDNF mRNAs are present in the brain, kidney, spinal cord,
and testis. Expression levels are low in adrenal gland, bone
marrow, pancreas, small intestine, uterus, and some other tis-
sues. In the adult brain, all antiBDNF transcripts are expressed
at similar levels in all brain regions analyzed. We found that
hundreds of different noncoding RNAs might be generated from
the antiBDNF gene as a result of alternative splicing.
Alternatively spliced isoform diversity is common to many
eukaryotic organisms and it is particularly widely used in the
nervous system [34]. Interestingly, antiBDNF is not present in
rodents [16,17]. antiBDNF ESTs are also not available for
chimpanzee and rhesus monkey although highly homologous
sequences are present in the genomes of these animals (data not
shown). All this suggests that antiBDNF could have evolved
during primate/hominid evolution, as was proposed also by Liu
et al. [19].
In this study we have shown that in the human brain BDNF
and antiBDNF transcripts form dsRNA duplexes in vivo. This
indicates that antiBDNF transcripts could have an important
role in the regulation of BDNF expression in human. Several
studies have shown that natural antisense transcripts (NATs) are
involved in the regulation of gene expression in eukaryotes
[35,36]. For example, NATs have been suggested to play an
405P. Pruunsild et al. / Genomics 90 (2007) 397–406important role in the regulation of several genes encoding
transcription factors that are important in eye development and
function in mice [37]. Characterization of overlapping tran-
scripts in various species indicates that this form of RNA-
mediated gene regulation represents a widespread phenomenon
[36,38]. NATs are particularly prevalent in the nervous system
where they regulate the expression of several genes [35]. In the
case of human BDNF and antiBDNF, the transcripts could act
as cis-antisense RNAs and generate siRNAs targeting one of the
initial transcripts, as do the natural cis-siRNAs described for
genes involved in salt tolerance in Arabidopsis thaliana [39].
Other possible regulatory functions of antiBDNF would be
direct inhibition of BDNF transcription or translation and/or
regulation of BDNF pre-mRNA splicing. Our results show that
the expression of antiBDNF and BDNF transcripts in different
tissues is not mutually exclusive and that the levels of BDNF
mRNA do not appear to be specifically reduced in tissues that
express high levels of antiBDNF transcripts. However, it is
possible that the antiBDNF transcripts could modulate the
levels of BDNF provided they are coexpressed in the same cell.
In conclusion, this detailed characterization of the human
BDNF gene locus opens up insights into the mechanisms
governing BDNF gene regulation in human.
Materials and methods
RNA isolation, RT-PCR, and cloning and sequencing of
RT-PCR products
Total RNAs from 23 human tissues were obtained from Clontech. Total
RNAs from postmortem adult human brain regions were isolated using the
RNAwiz RNA isolation reagent and treated with DNase (Ambion, USA)
according to the supplier's protocol. All experiments with human tissues were
approved by the local ethical committee. Five micrograms of total RNA was
reverse-transcribed to cDNA with an oligo(dT) primer (Proligo, France) and
SuperScript III reverse transcriptase using the SuperScript III First-Strand
Synthesis System (Invitrogen, USA). PCR amplification was carried out using
HOT FIREPol DNA polymerase (Solis Biodyne, Estonia), according to the
manufacturer's instructions. One-fortieth of the first-strand cDNA reaction mix
was used in the PCR. The exon-specific PCR primers were designed based on
the sequence of the human BDNF gene (NCBI Accession No. AF411339),
ESTs, and mRNA sequences from GenBank. Sequences for all primers are listed
in Table 1 of the supplementary material. The lengths of the PCR products using
the primer hBDNF_IXbAS in combination with the following primers were
hBDNF_IS, 472 bp; hBDNF_IIS, 610, 527, and 312 bp; hBDNF_IIIS, 347 bp;
hBDNF_IVS, 412 bp; hBDNF_VS, 673, 556, and 273 bp; hBDNF_VhS,
340 bp; hBDNF_VIS, 494, 387, and 369 bp; hBDNF_VIIS, 429 and 328 bp; and
hBDNF_IXS, 597 and 363 bp. The lengths of the longest PCR products with
haBDNF_1S in combination with the following primers were haBDNF_9AS,
947 bp, and haBDNF_10AS, 1483 bp. All products from the RT-PCR were
cloned into the pCRII-TOPO vector (Invitrogen) and sequenced.
Analyses of transcription start sites
The transcription start sites for the BDNF and antiBDNF transcripts were
detected with 5′ RACE using the GeneRacer Kit (Invitrogen) for full-length,
RNA ligase-mediated rapid amplification of 5′ cDNA ends, according to the
manufacturer's instructions. Briefly, 5 μg of total RNA from human hippo-
campus and cerebellum was dephosphorylated and decapped. The GeneRacer
RNA oligo was ligated to the decapped 5′ ends of the full-length mRNAs and
reverse transcription of the mRNAs was performed. RACE-ready cDNAs were
used as templates for subsequent PCR using the GeneRacer 5′ primer in
combination with BDNF exon-specific primers (Supplementary Table 1). ThePCR products were gel purified and cloned into the pCRII-TOPO (Invitrogen)
vector and verified by sequencing.
BDNF promoter–CAT reporter plasmids and CAT assay
PCR was performed to amplify promoter fragments of the human BDNF and
antiBDNF genes with the appropriate primers (Supplementary Table 1). Human
genomic DNAwas used as a template. The amplified fragments were cloned into
the pBL-CAT2 plasmid upstream of the coding region of the CAT gene,
replacing the thymidine kinase promoter, and verified by sequencing. HEK293T
and N2a cells were used for the analysis of promoter activities. The cells were
maintained in Dulbecco's modified Eagle's medium supplemented with 10%
fetal calf serum at 37°C in a 5% CO2 atmosphere. Transfection of cells with the
promoter–CAT reporter plasmids was performed with FuGENE 6 (Roche
Diagnostics, USA) according to the supplier's instructions. The transfected cells
were harvested 40 h after transfection. The samples were incubated with 14C-
labeled chloramphenicol and acetyl-CoA and the radioactive products were
separated by thin-layer chromatography silica gel (Merck, USA) and visualized
by autoradiography as described before [15].
BDNF/antiBDNF RNA duplex analyses
Ten micrograms of human cerebellar RNA, isolated with RNAwiz
(Ambion), was treated with DNase (Ambion Turbo DNA-free) for 30 min at
37°C according to the manufacturer's instructions, precipitated, and treated with
RNase A/T1 (Ambion) for 30 min at 37°C in RNase buffer (300 mM NaCl,
10 mM Tris, pH 7.4, and 5 mM EDTA). The reaction was terminated with
0.4 mg/ml proteinase K (Roche) in 200 mM Tris, pH 7.4, 25 mM EDTA, and 1%
SDS for 30 min at 37°C, and the dsRNA was phenol/chloroform extracted.
cDNA was synthesized from this dsRNA using the BDNF/antiBDNF
complementary region-specific primer Dup_S1 (Supplementary Table 1) with
Superscript III (Invitrogen) according to the manufacturer's instructions in the
presence of 5% DMSO. In subsequent RNA duplex detection PCR 1/20 of the
cDNA was used along with primers specific for the BDNF/antiBDNF
complementary region, Dup_S1 and Dup_AS (Supplementary Table 1; product
size 156 bp). Primer haBDNF_1S recognizing antiBDNF exon 1 in combination
with Dup_S2 (Supplementary Table 1; product size 490 bp) was used for
detection of ssRNA contamination. In addition, a −RT reaction was used for
detection of genomic DNA contamination using primers Dup_S1 and Dup_AS.
All PCRs were performed as follows: 40 cycles of 94°C for 30 s, 57°C for 30 s,
and 72°C for 30 s.
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